… and outcome of acute kidney injury (AKI) in patients with cardiorenal syndrome type 1 (CRS-…
Summary: We performed a systematic review and meta-analysis. CRS-1 was defined by AKI …

… investigate the composite of cardiorenal outcome from a systematic review and meta-analysis
of specific CKD trials and assess indirectly the clinical outcome between SGLT2 inhibitors …

… In trials of intravitreal VEGFi, we did not identify an increased risk of cardiorenal outcomes,
although these outcomes were reported in only a minority of cases. There was an increased …

… meta-analysis was to provide an update of all large CVOTs with SGLT-2 inhibitors to assess
their cardiorenal … risk of renal outcome by 35%, the present meta-analysis including ten …

… co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network
meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2 …

… In this meta-analysis study, we included those randomized trials which were designed to …
outcomes among T2D or non-T2D patients. The primary outcome for this meta-analysis was …

… this network meta-analysis … cardiorenal outcomes in patients with T2D, HF, or CKD. The
endpoints of interest for this network meta-analysis were the following eight cardiorenal outcomes…

… concealment, blinding, incomplete outcome data, and selective outcome reporting. Risk of
… Statistical analysis The primary efficacy outcome for this meta-analysis was the effect of GLP…

… There is a need for further analysis adjusting relevant cardiorenal risk factors. Last, this study
focused on cardiorenal efficacy outcomes and did not assess safety outcomes associated …

… from randomized cardiovascular (or cardiorenal) outcome trials finds that SGLT2 inhibitors
… Among the three classes of GLDs, in addition to their different effects on cardiorenal events, …